ClinicalTrials.gg
RecruitingNCT05508360LOPAIN2Updated Jul 27, 2026

"Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2)

An interventional study of PerQdisc Nucleus Replacement System in Degenerative Disc Disease and Chronic Low-back Pain, sponsored by Spinal Stabilization Technologies. Recruiting at 11 sites in 5 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-07-27.

Sponsored by Spinal Stabilization Technologies · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Not applicable
Ages
22 Years and older
Sex
All
01

Study summary

This study will be a prospective, open-label, multi-center study including 72 patients that will collect additional safety and efficacy data for the Spinal Stabilization Technologies PerQdisc Nucleus Replacement System.

Read the detailed description

This study will be a prospective, open-label, multi-center study that will collect additional safety and efficacy data for the minimally invasive PerQdisc Nucleus Replacement Device (NRD). Patients will have degenerative disc disease (DDD) in one or more lumbar discs. The NRD is used for surgical replacement of a single nucleus pulposus between spinal lumbar discs L1-S1 using any standard anterior, standard lateral, or minimally invasive posterolateral surgical approach. Currently the surgical gold standard involves spinal fusion of the affected vertebral bodies, reducing range of motion and increasing stress on other vertebral bodies. The goal of nucleus replacement is to reduce chronic low back pain by maintaining disc height while preserving range of motion.

02

Conditions studied

  • Degenerative Disc Disease
  • Chronic Low-back Pain

Keywords

  • Degenerative Disc Disease
  • DDD
  • Chronic Low Back Pain
  • cLBP
  • Disc Herniation
  • Nucleus Replacement
  • Low Back Pain
03

In context

Intervertebral Disc Degeneration

462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.

This study's planned enrollment of 72 is above the median of 60 across 256 interventional studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Spinal Stabilization Technologies is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is skeletally mature aged 22-70.
  • Patient has Degenerative Disc Disease (DDD) at one or more levels between L1 and S1 but the discogenic pain must be limited to a single level.
  • Patient has adequate disc height (6mm) at the level to be treated
  • Patient has exhausted a minimum of 6 months of conservative treatment for their back (e.g. physical therapy, medications, injections, life style changes, etc).
  • Patient has a preoperative Oswestry Disability questionnaire score ≥ 40 out of 100 points (40/100)
  • Patient has a low back pain Visual Analog Scale (VAS) ≥ 40 mm (4 cm)
  • Patient has signed the approved Form.
  • All surgeries must be approved by the Medical Advisory Board (MAB)

Exclusion criteria

Exclusion Criteria:

  • Patient has less than 6 mm of disc height.
  • Patient has had prior lumbar spine surgery (nucleoplasty at non-index level is considered acceptable).
  • Patient has had spinal fusion in the lumbar or thoracic intervertebral spaces. Cervical fusion is allowed as long as there are no neurologic deficits in the lower extremities.
  • Patient has spondyloarthropathy or other spondylolisthesis greater than 2 mm.
  • Patient has congenital moderate or severe spinal stenosis or epidural lipomatosis.
  • Patient has significant facet disease. Significant is defined as pain improvement of 80% or more following image-guided medial branch blocks of the target level according to SIS guidelines (diagnostic, contrast controlled).
  • Patient has any known active .
  • Patient has previously undergone or currently on therapy. used to treat inflammation are allowed.
  • Patient has active or local systemic infection.
  • Patient has been diagnosed with hepatitis, rheumatoid arthritis, lupus erythematosus, or other disease including AIDS, ARC and .
  • Patient has diabetes mellitus (Type 1 or 2) requiring daily insulin management.
  • Patient has osteopenia of the spine (T-score of -1.0 or lower). A DEXA scan should be performed to rule out patients considered at risk for osteopenia.
  • Patient has morbid obesity defined as a (BMI) more than 40 or a weight of more than 45 kg (100 lbs.) over ideal body weight.
  • Patient has a known allergy to silicone or barium sulfate.
  • Patient has a significant disc herniation at the level to be treated. Significant is defined as a large, extruded herniation that creates a risk for expulsion.
  • Patient has a significant Schmorl's node in the level to be treated. Significant is defined as a large, rectangular or irregular shaped node that has an associated active inflammatory process (Modic I changes).
  • Patient has motion of less than 3 degrees on pre-operative lateral flexion/extension radiographs.
  • Patient belongs to a vulnerable population or has a condition such that his/her ability to provide , comply with follow-up requirements, or provide self-assessments is compromised (e.g. developmentally, disabled, prisoner, chronic alcohol/ substance abuser)

Intraoperative Exclusion Criteria:

  • Protrusion of the 20A Imaging Balloon up to or beyond the outer margin of the vertebra during the imaging steps.
  • Patient has a violated endplate as determined by imaging balloons during fluoroscopy.
  • Patient has a disc space that is too narrow for implantation. MIPL Specific
  • Poor radiological visualization of Kambin's triangle.
  • Sustained irritation of the exiting nerve root during any aspect of the annular dilation technique (leg movement or if performing with electrical monitoring) in spite or repositioning instruments.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Lumbar Disc Nucleus Replacement

    All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.

    Device: PerQdisc Nucleus Replacement System

Interventions

  • DevicePerQdisc Nucleus Replacement System

    Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.

06

What researchers measure

Primary outcomes

  1. Perfromance: ODI

    Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool

    Time frame: 6 months

  2. Perfromance: ODI

    Change in in Oswestry Disability Index (ODI) comparing baseline to follow up visits using a patient-reported outcome tool

    Time frame: 12 months

  3. Performance: VAS

    Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)

    Time frame: 6 months

  4. Performance: VAS

    Change in back pain as measured by the 100 - millimeter Visual Analog Scale (VAS)

    Time frame: 12 months

  5. Safety: Expulsion & Device Failure

    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

    Time frame: 6 months

  6. Safety: Expulsion & Device Failure

    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

    Time frame: 12 months

Secondary outcomes

  1. Safety: Revision Surgery

    Incidence of revision surgery

    Time frame: 6 months, 12 months, and 5 years

  2. Safety: Expulsion & Device Failure

    Incidence of device expulsion and device failure following surgery based on follow up X-rays and MRI's

    Time frame: 5 years

  3. Performance: Disc Height

    Preservation of intervertebral disc height (in mm) as measured on MRI post-surgery compared to baseline

    Time frame: 6 months, 12 months, and 5 years

  4. Performance: RoM

    Preservation of range of movement (expressed in degrees) at the index and adjacent levels at baseline compared to follow-up using flexion/extension radiographs

    Time frame: 6 months, 12 months, 5 years

  5. Safety: Neurological Status

    Maintenance of baseline neurologic status through physical assessment evaluating nerve compression at baseline and post-surgical follow-up using pain, motor strength, and sensation feedback from the patient on a 0 (no compression) to 5 (major compression) scale

    Time frame: 6 months, 12 months, and 5 years

  6. Performance: Analgesic Score

    Change in level of pain medication used comparing baseline to follow up visits based on a medication scale ranging from 0 (no meds) - 4 (high dose opioids)

    Time frame: 6 months, 12 months, and 5 years

  7. Safety: SAE

    Incidence of serious adverse events that are related to the surgical procedure or Incidence of Serious Adverse Events related to the surgical procedure or device

    Time frame: 6 months, 12 months, and 5 years

07

Study locations

4 of 11 sites recruiting
  • CIGE: Centro de Imunologia y Genetica
    Medellín, Antioquia, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Fundacion Hospitalaria San Vicente de Paul
    Medellín, Antioquia, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Cediul S.A.
    Barranquilla, Atlántico, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Fundación Campbell
    Barranquilla, Atlántico, Colombia
    Withdrawn

    Not enrolling at this site.

  • Sabbag Radiólogos S.A.
    Barranquilla, Atlántico, Colombia
    Withdrawn

    Not enrolling at this site.

  • Sociedad de Cirugia de Bogota- Hospital de San Jose
    Bogotá, D.C., Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Clínica Imbanaco de Cali S.A.
    Cali, Valle del Cauca Department, Colombia
    Active, not recruiting

    Not enrolling at this site.

  • Life Science Center for Innovation Hospital Clinica Biblica
    San José, Costa Rica
    Recruiting
  • Pacífica Salud Hospital Punta Pacífica
    Panama City, Provincia de Panamá, Panama
    Recruiting
    • C&M Research S.A. · Contactinfo@candmresearch.org · +507 6860-4953
    • Dr. Ricardo Bermudez, MD · Principal investigator
  • Sanatario Americano
    Asunción, 1101, Paraguay
    Recruiting
  • Republican Specialized Scientific Practical Medical Center of Endocrinology named after Academician Y.Kh. Turakulova
    Tashkent, Uzbekistan
    Recruiting
    • Dr. Abdufarrukh Karimov · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05508360
Lead sponsor
Spinal Stabilization Technologies
Responsible party
Sponsor
First posted
Aug 19, 2022
Start date
Aug 22, 2022
Primary completion
Aug 22, 2027 (estimated)
Completion
Aug 22, 2030 (estimated)
Last update
Jul 27, 2026

Study contacts

Maren Lange
Contact
mlange@sstspine.com
8004841588
Molly Bond
Contact
mbond@sstspine.com
1 (715) 577-7527
Michael Hess, MD
study chair · London Spine Clinic/ATOS-Klinik

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion